ALL libraries (COBIB.SI union bibliographic/catalogue database)
  • Asthma treatment outcome in children Is associated with vascular endothelial growth factor A (VEGFA) polymorphisms
    Žavbi, Mateja ...
    Background: Asthma is a common chronic disease characterized by airway inflammation and structural remodeling. Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, is ... elevated in asthma patients. VEGF contributes to airway responsiveness and remodeling. It has been shown that treatment of asthma patients decreases VEGF levels, and inhibition of VEGF diminishes asthma symptoms in mice. Therefore, polymorphisms in the vascular endothelial growth factor A (VEGFA) gene might be associated with asthma treatment response. Methods: This study enrolled 131 children with asthma treated with different therapies - specifically, the inhaled corticosteroid (ICS) fluticasone propionate or the leukotriene receptor antagonist (LTRA) montelukast. We performed an association analysis between improvement of lung function - assessed by measurement of the percentage of the predicted forced expiratory volume in 1 second (%predicted FEV(1)), the ratio between the FEV(1) and the forced vital capacity (FEV(1)/FVC) after 6 and 12 months of treatment, and asthma control after 12 months of treatment - and two polymorphisms, rs2146323 and rs833058, in the VEGFA gene. Results: Polymorphism rs2146323 A>C in VEGFA was associated with response to ICS therapy. Asthma patients with the AA genotype had a greater improvement in the%predicted FEV(1) than those with the AC or CC genotype (p = 0.018). Conversely, the AA genotype in rs2146323 was associated with uncontrolled asthma in patients regularly receiving LTRA therapy (p = 0.020) and a worse FEV(1)/FVC ratio in patients who episodically used LTRA therapy (p = 0.044). Furthermore, polymorphism rs833058 C>T was associated with treatment response to episodically used LTRA therapy. A subgroup of patients with the TT genotypehad an improvement in the %predicted FEV(1), compared with no improvement in patients with the CT or CC genotype (p = 0.029). (Abs. trunc. at 2000 ch.)
    Source: Molecular diagnosis & therapy. - ISSN 1177-1062 (Vol. 16, iss. 3, 2012, str. 173-180)
    Type of material - article, component part
    Publish date - 2012
    Language - english
    COBISS.SI-ID - 29912793
    DOI

source: Molecular diagnosis & therapy. - ISSN 1177-1062 (Vol. 16, iss. 3, 2012, str. 173-180)
loading ...
loading ...
loading ...

Shelf entry